Who is not doing well?
They have navigated through a fire storm of vicious attacks by powerful forces with huge resources and motivation to take them down and are still afloat.
They restructured the trial multiple times and effectively dealt with false progress, an FDA hold, dozen of bogus lawsuits, securing continued financing, etc . . .
The trial is taking far longer than any of us imagined or wanted but looks like it is on course for approval with eye popping Overall Survival stats.
Everyone should be raving about their management of these savage attacks that are preventing and delaying what appears to be effectively a cure for > 30% of the GBM patients is really unconscionable.
This will be a Harvard Business School case study some day on how a small bio start up successful gained approval when many others in this situation have failed in the past.
News 
Market Data 
Discover 
